Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New laser zaps eye pressure in seconds for glaucoma patients

NCT ID NCT07281391

Disease control Sponsor: Mann Eye Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new laser treatment called Direct Selective Laser Trabeculoplasty (DSLT) for people with pigmentary glaucoma, a type of glaucoma that can lead to vision loss. The laser is applied directly through the eye's surface in just a few seconds, aiming to lower high eye pressure. Researchers will follow 45 adults for up to 12 months to see how well the treatment works and if it reduces the need for glaucoma medications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Direct Selective Laser Trabeculoplasty (DSLT) device
What this could lead to
If successful, DSLT could offer a quick, non-invasive way to lower eye pressure in pigmentary glaucoma, potentially reducing the need for daily eye drops.
What could go wrong
This is a small, early study with only 45 participants and no comparison group. The results may not apply to all patients, and the pressure-lowering effect might not last long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 45 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligible test subjects will be adult patients with pigmentary dispersion syndrome with elevated IOP or mild to moderate (based on AAO Preferred Practice Program criteria) pigmentary glaucoma with glaucomatous optic neuropathy and corresponding visual field/RNFL loss.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients with pigmentary dispersion syndrome with elevated IOP or mild to moderate (based on AAO Preferred Practice Program criteria) pigmentary glaucoma with glaucomatous optic neuropathy and corresponding visual field/RNFL loss. * Treatment naive, or washed out IOP ranging from ≥18-34 mmHg * Central corneal thickness (CCT) 480-600 µm * Able to complete medication washout and follow-up Exclusion Criteria: * Prior incisional glaucoma surgery or glaucoma-related procedures in the study eye * Prior laser trabeculoplasty \<3 years * Prior intraocular surgery and refractive surgery, except for cataract surgery unless greater than 2 years * Patients anticipating cataract surgery within the follow-up period * History of ocular inflammation and infection * All other secondary glaucoma including exfoliative * Patients unable to have DSLT treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pigmentary dispersion glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

open-angle glaucoma pigment dispersion syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pigmentary dispersion glaucoma Pigmentary dispersion syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mann Eye Institute

    RECRUITING

    Houston, Texas, 76134-2099, United States